Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
- 29 September 2025
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 209, 108783
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Netherlands Ministry of Health Welfare and Sport
- Dutch Cancer Society
This publication has 38 references indexed in Scilit:
- LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA studyAnnals of Oncology, 2024
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyAnnals of Oncology, 2023
- 329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinibAnnals of Oncology, 2022
- LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 studyAnnals of Oncology, 2022
- Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practiceThe Journal of Pathology, 2022
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerAnnals of Oncology, 2022
- 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinibAnnals of Oncology, 2021
- Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy RecommendationsThe Oncologist, 2020
- Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisionsMolecular Oncology, 2019